A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG

CS0159 (Linafexor)

Oral QD

Trial Locations (17)

28557

Lucas Research, Morehead City

30349

Oracle Clinical Research, College Park

32159

Ocala GI Research, Lady Lake

34471

Gastroenterology Associates of Ocala, Ocala

70072

Metropolitan Gastroenterology Associates - Westbank Office and Endoscopy, Marrero

78215

The Texas Liver Institute, Inc., San Antonio

78229

Clinical Trials of Texas, LLC, San Antonio

92704

Velocity Clinical Research - Santa Ana, Santa Ana

90247-3586

National Research Institute - Gardena, Gardena

90255-2959

Velocity Clinical Research, Huntington Park, Huntington Park

91402-3022

Velocity Clinical Research - Panorama City, Panorama City

34211-4930

Florida Research Institute, Lakewood

33014-5602

San Marcus Research Clinic, Inc - Miami, Miami

33016-1518

Floridian Clinical Research, LLC - Miami Lakes, Miami Lakes

20770-6702

Raja M. Din MD, PLLC - Gastroenterology & Hepatology, Greenbelt

78757-7571

Texas Liver Institute (TLI) - Austin, Austin

77099-4307

Pioneer Research Solutions Inc - Houston - Stancliff Rd, Houston

Sponsors
All Listed Sponsors
collaborator

Laboratory Corporation of America

INDUSTRY

lead

Cascade Pharmaceuticals, Inc

OTHER